CDT News & Events

CDT Equity announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, were duly passed by the stockholders. "Following the successful passing of all the proposals at yesterday's Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8M", said Dr. Andrew Regan, CEO. "Utilizing cutting edge AI and an algorithmic approach, CDT can complete analysis on more than 3,000 diseases in a matter of hours, that might conventionally have taken pharma companies up to 5 years. It's a breakthrough in drug re-purposing that uniquely positions the Company through a novel approach, which combined with CDT's focus on developing IP is expected to revolutionize the approach of pharmaceutical companies. CDT Equity is now moving to a phase of out-license deals with disease specific partners and funds."

CDT Equity notes the announcement from Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform through the curation of a rare disease signature database. Sarborg announced that it has curated a database containing approximately 1,700 rare disease signatures, building upon its existing disease signature library of more than 1,600 conditions, as well as its agrochemical and bacterial signature datasets previously announced. According to Sarborg, structuring rare diseases as machine-interpretable biological signatures enables rapid analysis of disease relationships and potential therapeutic opportunities that would traditionally require extensive discovery and preclinical research. CDT has agreed a new collaboration with Sarborg to map CDT's asset portfolio, including certain combination therapies, against this expanded rare disease database. CDT intends to use this data to maximize its IP position based on the outcome and to explore commercialization through external partnership opportunities. CDT holds a 20% equity stake in Sarborg and continues to utilize its cross-industry signature intelligence platform.

The company said, "The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ongoing evaluation and out-licensing discussions and continues to assess pathways to maximize the commercial and strategic potential of these assets. The Company believes this diversified asset base provides several avenues through which value may be realized. In addition, CDT recently completed its strategic acquisition of a 20% equity stake in Sarborg for an initial consideration of $115 million, providing shareholders with direct participation in a growing agentic AI signature intelligence business whose activities extend beyond pharmaceuticals into additional sectors, including bacteria and agrochemicals. The consideration was satisfied through the issuance of common stock and pre-funded warrants, reinforcing its balance sheet. CDT believes the transaction enhances its overall asset position and broadens its exposure to scalable, data-driven opportunity sets across multiple industries. The Company believes it is in a strong position to evaluate opportunities that could be materially transformative to its balance sheet and market capitalization. CDT continues to assess strategic transactions, partnerships and corporate initiatives that may enhance its financial position and long-term growth profile. Subject to customary approvals, the Company also expects to retain access to capital markets tools that may further strengthen its financial flexibility and strategic optionality."